Detail akcie Vaxcyte Rg online

Business Summary: Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vaxcyte Inc revenues was not reported. Net loss increased 59% to $520.1M. Higher net loss reflects Research and development increase from $232.1M to $497.7M (expense), Stock-based Compensation in R&D increase of 78% to $54.5M (expense), Stock-based Compensation in SGA increase of 62% to $48.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.78 to -$3.82.